SU2C announces three research teams to study gastroesophageal cancer

Health Canada approves Keytruda for gastroesophageal cancer

Health Canada approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

April 26, 2024

Vol.50 No.17

In Brief

AACR recognizes 2023-2024 research grantees

The American Association for Cancer Research has named its newest class of grant recipients.

April 05, 2024

Vol.50 No.14

Clinical Roundup

One in five people with cancer participate in medical research studies, Fred Hutchinson study shows

Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network, and peer institutions released findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer, or 21.9%, participate in some form of clinical research.

April 05, 2024

Vol.50 No.14

In Brief

AACR publishes annual impact report

The American Association for Cancer Research presented its 2023 Annual Impact Report.

March 08, 2024

Vol.50 No.10

In Brief

Medical College of Wisconsin constructing cancer research building

The Medical College of Wisconsin faculty, researchers, staff, and students were invited to sign a construction beam that will soon become a permanent fixture of the new MCW Cancer Research Building.

March 08, 2024

Vol.50 No.10

Clinical

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.

February 23, 2024

Vol.50 No.08

By Matthew Bin Han Ong